ABSTRACT
Since its initial description in 1893, alpha-chloralose has undergone extensive pharmacologic evaluation. It has been characterized as a compound possessing potent CNS activity and has been evaluated in humans and animal models for its therapeutic properties. Though the toxicity of the compound prohibits its use as a human therapeutic agent, it has been employed widely as an animal anesthetic in the laboratory setting. A thorough search of the literature reveals that alpha-chloralose is second only to sodium pentobarbital as the primary anesthetic agent in acute cardiovascular studies where the preservation of myocardial function is a primary consideration. The literature also shows that alpha-chloralose is the subject of much controversy. The question as to whether alpha-chloralose is a true anesthetic or an immobilizing agent with sedative-hypnotic properties has important implications in light of the current emphasis on ethics in animal research.
Subject(s)
Anesthesia, General , Chloralose , Dogs , Animals , Information Systems , MEDLARS , United StatesABSTRACT
PIP: The effects of deliberate omission of a Microgynon 30 (150 mcg of levonorgestrel and 30 mcg of ethinyl estradiol) tablet in the early and latter course of the pills were investigated by hormonal profiles (published figuratively) of luteinizing hormone, follicle stimulating hormone (FSH), estradiol 17-beta, and progesterone. 3 women deliberately missed Day 19, and blood samples were drawn from Day 17-24; 7 women deliberately omitted Day 4 treatment, and their blood was drawn from Day 1-7. Blood levels, contrary to previous findings which noted a sharp rise in FSH and near zero titers of steroids after omission of a Microgynon 30 tablet unintentionally, did not show any marked rise either early or late in the cycle omission. Cervical mucus examined in 6 of the subjects displayed physical characteristics associated with an uninterrupted ancillary contraceptive effect.^ieng
